CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Discovery Corporation, a biotechnology company developing novel classes of therapeutics and bioassays using its proprietary DNA Programmed Chemistry™ (DPC™) platform, today announced that it has appointed Michael D. Taylor, Ph.D. as President and Chief Executive Officer and to the company’s Board of Directors.
“We are thrilled to welcome an experienced executive of Mike’s caliber to Ensemble Discovery,” said Noubar Afeyan, Ph.D., Chairman of Ensemble Discovery and Managing Partner and CEO of Flagship Ventures. “Mike brings a wealth of experience in the pharmaceutical industry and a track record of success that will be critical as we further develop our drug discovery and biodetection programs.”
